| |||||||||

Revenue by Geography (USD) Annual | ||||||||
|---|---|---|---|---|---|---|---|---|
| FISCAL YEAR ENDING |
|
31-DEC 2004 |
31-DEC 2005 |
31-DEC 2006 |
31-DEC 2007 |
31-DEC 2008 |
||
| Revenue - International | 1.70B | 2.13B | 2.49B | 2.88B | 3.23B | |||
| Revenue - US | 8.85B | 10.3B | 11.8B | 11.9B | 11.8B | |||
| Total Revenue | 10.6B | 12.4B | 14.3B | 14.8B | 15.0B | |||
Revenue by Segment (USD) Annual | ||||||||
|---|---|---|---|---|---|---|---|---|
| FISCAL YEAR ENDING |
|
31-DEC 2004 |
31-DEC 2005 |
31-DEC 2006 |
31-DEC 2007 |
31-DEC 2008 |
||
| Revenue - Other Revenues | 573M | 408M | 410M | 460M | 316M | |||
| Revenue - Other Products | 51.0M | 60.0M | 103M | 238M | 240M | |||
| Revenue - Human Therapeutics | 10.6B | 12.4B | 14.3B | 14.8B | 15.0B | |||
| Revenue - Aransep | 2.47B | 3.27B | 4.12B | 3.61B | 3.14B | |||
| Revenue - Epogen | 2.60B | 2.46B | 2.51B | 2.49B | 2.46B | |||
| Revenue - Neulasta | 1.74B | 2.29B | 2.71B | 3.00B | 3.32B | |||
| Revenue - Neupogen | 1.18B | 1.22B | 1.21B | 1.28B | 1.34B | |||
| Revenue - Enbrel | 1.90B | 2.57B | 2.88B | 3.23B | 3.60B | |||
| Revenue - Sensipar | 37.0M | 157M | 321M | 463M | 597M | |||
| Total Revenue | 10.6B | 12.4B | 14.3B | 14.8B | 15.0B | |||
| ||||||